This protocol addresses hyperthyroidism arising in the setting of amiodarone-induced thyrotoxicosis type 1 — a distinct subtype characterised by excess thyroid hormone production rather than glandular destruction.
Amiodarone-induced thyrotoxicosis is classified as type 1 (thyroid hormone overproduction) or type 2 (thyroid tissue destruction). The two types differ in mechanism and require different management strategies. This protocol is specific to type 1.
Management in this setting centres on antithyroid medications. A critical consideration is the amiodarone itself: whether it can be safely stopped requires careful assessment of the patient's underlying cardiac status before any change is made. The full sequenced regimen and decision criteria are in the protocol below.
Amiodarone-induced thyrotoxicosis can be classified as type 1 (thyroid hormone overproduction, treated with antithyroid medications) or type 2 (thyroid tissue destruction, treated with steroids).
Amiodarone should not be discontinued unless it can be stopped safely, without triggering cardiac complications.